ResearcherUniversity of North Carolina at CharlotteActive in the last 2 years
Juan Luis Vivero-Escoto
Matched on ORCID iD 0000-0001-7400-2963; OpenAlex author ID A5040672156; NIH RePORTER profile ID 10334039. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 2)
- Trials
- 0
- Grants
- 2
- Labs led
- 1
- Collaborators
- 5
2015: 1 grant · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 3 papers · 2023: none · 2024: none · 2025: none · 2026: 1 grant
Papers 3
- Advanced Nanoengineering Approach for Target-Specific, Spatiotemporal, and Ratiometric Delivery of Gemcitabine-Cisplatin Combination for Improved Therapeutic O… Last author DOI 10.1002/smll.202104449↗
- Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. First author DOI 10.1016/j.addr.2022.114357↗
- Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer. Last author DOI 10.1016/j.jconrel.2022.05.019↗
Grants 2
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mubin Tarannum · 3 shared papers, 2022 · strength 0.72
- Paper Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. DOI 10.1016/j.addr.2022.114357↗
- Paper Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer. DOI 10.1016/j.jconrel.2022.05.019↗
- Paper Advanced Nanoengineering Approach for Target-Specific, Spatiotemporal, and Ratiometric Delivery of Gemcitabine-Cisplati… DOI 10.1002/smll.202104449↗
- Pinku Mukherjee · 2 shared papers, 2022 · strength 0.39
- Didier Dréau · 1 shared paper, 2022 · strength 0.20
- Shan Yan · 1 shared paper, 2022 · strength 0.19
- Md Akram Hossain · 1 shared paper, 2022 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.